IceCure Medical Gets FDA Nod for Breast Cancer Treatment
Ticker: ICCM · Form: 6-K · Filed: Oct 3, 2025 · CIK: 1584371
Sentiment: bullish
Topics: FDA-approval, medical-device, oncology
TL;DR
FDA approves IceCure's ProSense for older women's breast cancer.
AI Summary
On October 3, 2025, IceCure Medical Ltd. announced it received FDA marketing authorization for its ProSense® cryoablation system. This authorization specifically targets the treatment of low-risk breast cancer in women aged 70 and above.
Why It Matters
This FDA approval expands the potential market for IceCure's cryoablation technology, offering a new treatment option for a specific demographic of breast cancer patients.
Risk Assessment
Risk Level: medium — While FDA approval is positive, the specific target demographic and the company's overall financial health and market adoption rate present ongoing risks.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and recipient of FDA authorization.
- ProSense® (product) — The cryoablation system that received FDA marketing authorization.
- FDA (organization) — Regulatory body that granted marketing authorization.
FAQ
What specific condition has IceCure Medical Ltd. received FDA marketing authorization for?
IceCure Medical Ltd. received FDA marketing authorization for its ProSense® cryoablation for the treatment of low-risk breast cancer in women aged 70 and above.
On what date was this FDA authorization announced?
The announcement of the FDA marketing authorization was made on October 3, 2025.
What is the name of the product that received FDA authorization?
The product that received FDA marketing authorization is called ProSense®.
Which demographic is specifically targeted by this FDA authorization?
The FDA marketing authorization is for the treatment of low-risk breast cancer in women aged 70 and above.
What form was filed with the SEC regarding this announcement?
A Form 6-K was filed with the SEC, reporting the press release about the FDA marketing authorization.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 13.9 · Accepted 2025-10-03 16:01:20
Filing Documents
- ea0260242-6k_icecure.htm (6-K) — 13KB
- ea026024201ex99-1_icecure.htm (EX-99.1) — 23KB
- ea026024201ex99-2_icecure.htm (EX-99.2) — 22KB
- ex99-2_001.jpg (GRAPHIC) — 14KB
- 0001213900-25-096061.txt ( ) — 77KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: October 3, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2